Gerd Medication And Headache

Featured Article

The U.S. Food and Drug Administration (FDA) approved NEXIUM® delayed release capsules in children ages 12 to 17 for the short-term treatment of gastroesophageal reflux disease (GERD). NEXIUM was tested in adolescents ages 12 to 17 in a randomized, double-blind parallel group study in which a total of 149 patients, ages 12 to 17, with clinically diagnosed GERD were treated with either NEXIUM 20mg or NEXIUM 40 mg once a day for up to eight weeks. Reported side effects included headache,...

Read more

More information on "Gerd Medication And Headache"

From Our Experts

See more SharePosts »

From Our Sources

More on Acid Reflux »